Ark appeals negative EU decision on brain cancer gene therapy Cerepro
05 January 2010
Malini Guha
Please Login to read the full article.
05 January 2010
Malini Guha
Malini.guha@informa.com
Ark Therapeutics has appealed the CHMP's negative decision on its experimental brain cancer therapy Cerepro (sitimagene ceradenovec), which the company is hoping will become the first-approved gene therapy in the EU.
In December, the CHMP said that the results of the 236-patient Phase III...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Russian firm HSCI wins race to bring first gene therapy to market in Europe
- Merck & Co out-licences clinical-stage gene therapy asset to new start-up
- EU grant marks third cash injection in a month for Ark
- CHMP extensions for Roche's Tarceva, Novartis' Afinitor and Wyeth's Enbrel
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
